MARKET WIREMoomoo • 15h ago
Kamada(KMDA) Stock Options Chain | Quotes & NewsMoomoo report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
Why KMDA Stock dropped -3.14% Today — RQD Quant Desk Flash
$7.70 -3.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.64
Kamada Ltd. (KMDA) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $458.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on KMDA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is KMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Kamada Ltd. (NASDAQ: KMDA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $7.70 (-3.14% 1D, market cap $458.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KMDA ranks #312 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does KMDA compare to PRTA and MNPR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KMDA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PRTA (Prothena Corporation plc) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $455.9M) and MNPR (Monopar Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M). Among the 5-stock peer group, KMDA leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for KMDA?
▼
For Kamada Ltd. (KMDA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #312 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.64 (-0.76%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KMDA)Realized 20D OHLCV Swing Band: ±5.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY KMDA SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)
SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($12.8M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Macro Regime Fit7/20 pts (-13 pt drag)
Macro rate sensitivity & RSI-14 (49.7) create a -13 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$7.84-2.9% Next Q
57
Q2 (-2Q)Grade C-$7.61+4.3% Next Q
54
Q3 (-1Q)Grade C-$7.94-3% Next Q
52
CurrentGrade D$7.70-5.4% Hist 90D α
49
Trajectory: C (57) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a KMDA Turnaround Squeeze
While KMDA currently carries a cautious 49/100 (D) rating due to Macro Regime Fit (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.19) and Max Pain ($8.09) forces dealer call-delta covering toward $9.82.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $KMDA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KMDA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why KMDA Stock dropped -3.14% Today — RQD Quant Desk Flash
Kamada Ltd. (KMDA) dropped -3.14% to $7.70, trading at 41% of its 52-week range ($6.55 – $9.35). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 41% of its 52-week range ($6.55 – $9.35) with RSI-14 at 49.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.5% around $7.70 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $12.8M annual free cash flow.
Live KMDA Headlines & Catalysts
MARKET WIRETradingView • 18h ago
Kamada Ltd. Estimates – NASDAQ:KMDATradingView report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 21h ago
Stifel reiterates Kamada stock Buy rating on biosimilar expansionInvesting.com report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
At 8:30 a.m. ET on Nov. 9, investors can question Kamada's management live.Stock Titan report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
An 8:30 a.m. ET call will follow Kamada (KMDA) earnings on November 9, 2026.Stock Titan report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
(KMDA) Volatility Zones as Tactical TriggersStock Traders Daily report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
Kamada (KMDA) Sinks -3.14% as Volume Spikes on Downside 2026-10-30 - Dealer Gammahttps://www.dars.gov.et/ report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
Technical Reactions to KMDA Trends in Macro StrategiesStock Traders Daily report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 18h ago
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026Company to Host Conference Call at 8:30am ETREHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed
MARKET WIREYahoo • 14d ago
Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious cond
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KMDA)
- ✓Walkthrough of KMDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
KMDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.12%📐 HORIZONTAL RANGE
2026-11-02O $8.00H $8.00L $7.70C $7.70VOL 65.8K
RES: $9.69SUP: $6.64SMA50: $8.19SMA200: $8.02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
KMDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on KMDA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for KMDA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KMDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KMDA)
Health Care Rank #312 of 1016
⚔️ PRTA vs KMDA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (KMDA vs. PRTA, MNPR, BLSM, FTH)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Kamada Ltd. (KMDA) ranks #312 by composite RQD confidence (49/100, grade D) and #464 by equity capitalization ($458.8M). Within this direct 5-issuer industry benchmark cohort, KMDA leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. KMDA currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KMDA
ACTIVE
Kamada Ltd. | D | 49/100 | — | — | — | -3.14% | $458.8M | Benchmark Subject |
| PRTA Prothena Corporation plc | E | 26/100 | — | — | -35.0% | -4.62% | $455.9M | /prta-vs-kmda → |
| MNPR Monopar Therapeutics Inc. | E | 27/100 | — | — | -17.4% | -2.21% | $482.7M | /mnpr-vs-kmda → |
| BLSM BlossomHill Therapeutics Inc. | D- | 42/100 | — | — | — | -9.60% | $483.4M | /blsm-vs-kmda → |
| FTH Faeth Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -0.32% | $484.5M | /fth-vs-kmda → |
2. KMDA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTKamada Ltd. (KMDA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $458.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. KMDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs KMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Kamada Ltd. (NASDAQ: KMDA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $7.70 (-3.14% 1D, market cap $458.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KMDA ranks #312 in composite RQD confidence.
How does KMDA compare to PRTA and MNPR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KMDA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PRTA (Prothena Corporation plc) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $455.9M) and MNPR (Monopar Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M). Among the 5-stock peer group, KMDA leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for KMDA?
For Kamada Ltd. (KMDA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #312 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is KMDA trading relative to its 50-day, 200-day, and 52-week technical levels?
KMDA last traded at $7.70 (-3.14% on volume of 47,517 shares), positioning the stock -5.98% below its 50-day simple moving average ($8.19) and -3.99% below its 200-day simple moving average ($8.02). Across its 52-week range of $6.55 to $9.35, KMDA sits at the 41.1% percentile with a 14-day RSI of 49.7 (NEUTRAL RANGE) and an implied next-earnings move of ±5.5% ($7.28 to $8.12).
KMDA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is KMDA stock moving today?
Why KMDA Stock dropped -3.14% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 49/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
KMDA — Kamada Ltd.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:16:06Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, KMDA scores 49 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are as follows:
- Fundamental Cash Engine: 12 / 20 (ROIC 0%; FCF yield 0%). The rating's cash-generation pillar is weak, and the source data shows no measured return on invested capital or free cash flow yield. For a prospective investor, this means the business is not currently demonstrating the cash-earning power that typically supports valuation.
- Whale 13F Flow: 8 / 20 (institutional accumulation and options positioning). This is a below-midpoint reading, suggesting limited evidence of large institutional conviction in the source data.
- Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). The reading indicates modest insider-side confidence signals.
- Macro Regime Fit: 7 / 20 (beta 1.0; sector sensitivity). A beta of 1.0 means the stock is rated as moving in line with the broader market, and the low pillar score signals weak positioning for the prevailing regime per the rating.
- Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; debt/equity 0.5). This is the strongest pillar, indicating the balance sheet is comparatively the most defensible part of the thesis.
Taken together, the rating frames KMDA as a name where the balance sheet offers some stability, but cash generation, institutional support, and insider signals are not supportive. Upside drivers would need to come from improvements in cash returns or a shift in institutional positioning; the source data does not identify a valuation anchor (P/E and EV/EBITDA are not available in source data) against which to weigh the stock's $7.95 price. This is an educational summary of the rating, not personalized advice.
Open Questions
- What are the reported revenue, operating income, net income, and free cash flow figures, and what is the period-over-period trend?
- What are the company's specific products, approved indications, and key biosimilar programs referenced in the Stifel note?
- What is the outcome of the November 9, 2026 earnings and management call?
- What is the analyst consensus rating and price target distribution, and who are the major institutional or insider holders?
- What does the company's cash runway and debt maturity profile look like given a 0% FCF yield?
KMDA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Kamada Ltd. (KMDA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Moomoo • 15h ago
Kamada(KMDA) Stock Options Chain | Quotes & News Moomoo report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 18h ago
Kamada Ltd. Estimates – NASDAQ:KMDA TradingView report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 21h ago
Stifel reiterates Kamada stock Buy rating on biosimilar expansion Investing.com report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
At 8:30 a.m. ET on Nov. 9, investors can question Kamada's management live. Stock Titan report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
An 8:30 a.m. ET call will follow Kamada (KMDA) earnings on November 9, 2026. Stock Titan report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
(KMDA) Volatility Zones as Tactical Triggers Stock Traders Daily report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
Kamada (KMDA) Sinks -3.14% as Volume Spikes on Downside 2026-10-30 - Dealer Gamma https://www.dars.gov.et/ report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
Technical Reactions to KMDA Trends in Macro Strategies Stock Traders Daily report covering Kamada Ltd. (KMDA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
KMDA Bull vs. Bear Conversation Board — What's Your Call at $7.70?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KMDA 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $8.59 (+8.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is KMDA (D • RQD 49/100) a Buy at $7.95?
Welcome to the KMDA (Kamada Ltd.) Roar Pit. Current RQD Composite is 49/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $6.36 (-20.0%)
Spot @ $7.95 Pump the brakes on KMDA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on KMDA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Kamada Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $10.18 (+28.1%)
Spot @ $7.95 KMDA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on KMDA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $7.95 (52-wk range $6.55 - $9.35), any beat on forward guidance forces shorts and underweight funds to chase.